p-nitrophenyl galactose

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: p-nitrophenyl galactose
• 英文别名: p-Nitrophenyl galactopyranoside；(2R,3R,4S,5R)-2-(hydroxymethyl)-6-(4-nitrophenoxy)oxane-3,4,5-triol
• 化学式: C₁₂H₁₅NO₈
• 分子量: 301.253
• InChiKey: IFBHRQDFSNCLOZ-SCWFEDMQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  145
• 氢给体数：
  4
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  对苯二甲醇 、 p-nitrophenyl galactose 在 β-galactosidase 作用下， 以 phosphate buffer 为溶剂， 生成
  参考文献：
  名称：

  支链对称非碳水化合物多元醇的酶促糖基化

  摘要：

  摘要评价了三种糖苷酶，分别是来自Jack bean的α-甘露糖苷酶，米曲霉的β-半乳糖苷酶和米曲霉的β-N-乙酰基己糖苷酶催化非糖多元醇糖基化的能力。得到一系列纯的三（2-氨基乙基）氰尿酸，季戊四醇和双（羟甲基）苯的单糖基化衍生物，并通过NMR光谱表征。

  DOI：

  10.1080/07328309808001896

文献信息

• GLYCOMIMETIC COMPOUNDS AS ANTI-INFECTIOUS AGAINST PATHOGENS LECTINS
  申请人：Imberty Anne

  公开号：US20130252910A1

  公开（公告）日：2013-09-26

  The present invention relates to a calixarene-based glycosylated compound (I) having the formula: (I) wherein D is independently selected in the group comprising a —CH 2 -group, an oxygen atom, a sulphur atom, a sulfinyl group or a sulfonyl group, E is independently selected in the group comprising a hydrogen, an alkyl having from 1 to 10 carbon atoms, an aryl having from 6 to 20 carbon atoms, a nitrogen dioxide group, an azide group, an amino group, a guanidinium group, a halogen atom, a —CH 2 R group wherein R is a hydroxyl, a halogen, an amino group, a N(alkyl) 2 group, a NH(alkyl) group, or E represents a —CO—R′ wherein R′ is a hydrogen atom, a hydroxyl group or an amino, B represents a A-C group wherein A is independently selected in the group comprising an oxygen atom, a sulfur atom, a NH group or a (CH 2 ) i group, i being an integer from 1 to 10, C is independently selected in the group comprising a hydrogen, an alkyl, an alkenyl, an alkynyl, or C is a group of formula (II). The present invention also relates to a pharmaceutical composition characterized in that it comprises the said calixarene-based glycosylated compound (I), in combination with pharmaceutically acceptable carriers or diluents. The present invention also relates to the use of the said calixarene-based glycosylated compound (I) or the said pharmaceutical composition, for the manufacture of a drug intended to prevent or treat bacterial infections from pathogens that use lectins in the first steps of infection.

  本发明涉及一种基于杯芳烃的糖基化化合物（I），其化学式如下：（I）其中D在以下组中独立选择：—CH2基团、氧原子、硫原子、亚砜基或磺酰基；E在以下组中独立选择：氢、具有1至10个碳原子的烷基、具有6至20个碳原子的芳基、亚硝基团、叠氮基团、氨基、胍胺基、卤原子、— R基团（其中R是羟基、卤原子、氨基、N（烷基）2基团、NH（烷基）基团）或E代表—CO—R'（其中R'是氢原子、羟基或氨基），B代表A-C基团（其中A在以下组中独立选择：氧原子、硫原子、NH基团或（ ）i基团，i为1至10的整数），C在以下组中独立选择：氢、烷基、烯基、炔基，或C是化学式（II）的基团。本发明还涉及一种药物组合物，其特征在于它包括所述的基于杯芳烃的糖基化化合物（I），与药学上可接受的载体或稀释剂结合。本发明还涉及所述的基于杯芳烃的糖基化化合物（I）或所述的药物组合物的用途，用于制造用于预防或治疗利用凝集素进行感染起始阶段的病原体引起的细菌感染的药物。
• [EN] GLYCOMIMETIC COMPOUNDS AS ANTI-INFECTIOUS AGAINST PATHOGENS LECTINS<br/>[FR] COMPOSÉS GLYCOMIMÉTIQUES EN TANT QU'AGENTS ANTI-INFECTIEUX CONTRE DES LECTINES PATHOGÈNES
  申请人：CENTRE NAT RECH SCIENT

  公开号：WO2012076934A1

  公开（公告）日：2012-06-14

  The present invention relates to a calixarene-based glycosylated compound (I) having the formula : (I) wherein D is independently selected in the group comprising a –CH2 –group, an oxygen atom, a sulphur atom, a sulfinyl group or a sulfonyl group, E is independently selected in the group comprising a hydrogen, an alkyl having from 1 to 10 carbon atoms, an aryl having from 6 to 20 carbon atoms, a nitrogen dioxide group, an azide group, an amino group, a guanidinium group,a halogen atom, a –CH2 R group wherein R is a hydroxyl, a halogen, an amino group, a N(alkyl)2 group, a NH(alkyl) group, or E represents a –CO-R' wherein R' is a hydrogen atom, a hydroxyl group or an amino, B represents a A–C group wherein A is independently selected in the group comprising an oxygen atom, a sulfur atom, a NH group or a (CH2 )i group, i being an integer from 1 to 10, C is independently selected in the group comprising a hydrogen, an alkyl, an alkenyl, an alkynyl, or C is a group of formula (II). The present invention also relates to a pharmaceutical composition characterized in that it comprises the said calixarene-based glycosylated compound (I), in combination with pharmaceutically acceptable carriers or diluents. The present invention also relates to the use of the said calixarene-based glycosylated compound (I) or the said pharmaceutical composition, for the manufacture of a drug intended to prevent or treat bacterial infections from pathogens that use lectins in the first steps of infection.

  本发明涉及一种基于杯芳烃的糖基化化合物（I），其化学式为：（I），其中D在以下基团中独立选择：-CH2-基团、氧原子、硫原子、亚砜基团或磺基团，E在以下基团中独立选择：氢、碳原子数为1至10的烷基、碳原子数为6至20的芳基、二氧化氮基团、叠氮基团、氨基团、胍基团、卤素原子、- R基团，其中R为羟基、卤素、氨基、N（烷基）2基团、NH（烷基）基团，或E表示-CO-R'，其中R'为氢原子、羟基或氨基，B表示A-C基团，其中A在以下基团中独立选择：氧原子、硫原子、NH基团或( )i基团，i为1至10的整数，C在以下基团中独立选择：氢、烷基、烯基、炔基，或C为下式的基团（II）。本发明还涉及一种药物组合物，其特征在于它包括所述基于杯芳烃的糖基化化合物（I），结合具有药用接受的载体或稀释剂。本发明还涉及所述基于杯芳烃的糖基化化合物（I）或所述药物组合物的用途，用于制造预防或治疗利用凝集素在感染的最初阶段的病原体引起的细菌感染的药物。
• Compound for Use in Enzymatic Reaction and Mass Spectrometry Method
  申请人：HITACHI HIGH-TECHNOLOGIES CORPORATION

  公开号：US20190330140A1

  公开（公告）日：2019-10-31

  A compound used in the conventional enzymatic reactions and mass spectrometry methods needs to be altered with respect to the structure thereof as a substrate compound, such as the length of an alkyl chain contained therein, depending on the type of a target enzyme, and therefore has the problem that the conditions for the mass spectrometry on a product compound are undesirably varied and the sensitivity is deteriorated. In the present invention, a compound is provided, which can be used in an enzymatic reaction and a microanalysis method both for detecting a trace component stably and with high sensitivity. The compound according to the present invention is characterized by having a nitrogen atom, an amide bond and a glycosidic bond at specific sites, respectively, has high reactivity with an enzyme, and can provide a compound capable of being detected very easily with a mass spectrometer.

  传统酶反应和质谱法中使用的化合物需要根据目标酶的类型对其作为底物的结构进行改变，例如其中所含烷基链的长度，因此会出现质谱分析产物化合物的条件不稳定和灵敏度降低的问题。本发明提供了一种化合物，可用于酶反应和微量分析方法，以稳定且高灵敏度地检测微量成分。本发明的化合物具有特定位置的氮原子、酰胺键和糖苷键，具有与酶高反应性，并能够提供一种能够非常容易地被质谱仪检测到的化合物。
• Hybridoma secreting a monoclonal antibody specific for 5-bromo and 5-iododeoxyuridine and reagent for measuring cellular proliferation
  申请人：UNIVERSITY OF MIAMI

  公开号：EP0102228A2

  公开（公告）日：1984-03-07

  Cells synthesizing DNA are detected in a rapid, nonradioactive assay using the monoclonal antibody reagent secreted by the hybridoma produced by fusion of a myeloma cell, preferably murine plasmacytoma cell, with an animal antibody producing cell, preferably a mouse spleen cell, immunized with the conjugate of 5-bromouridine or 5-iodouridineand an albumin-carrier molecule. The antibody is specific for 5-bromodeoxyuridine or 5-iododeoxyuridine.

  用 5-溴脱氧尿苷或 5-碘脱氧尿苷与白蛋白载体分子的共轭物免疫骨髓瘤细胞（最好是小鼠浆细胞瘤细胞）与动物抗体产生细胞（最好是小鼠脾脏细胞）融合产生的杂交瘤分泌的单克隆抗体试剂，通过快速、非放射性检测法检测合成 DNA 的细胞。该抗体对 5-溴脱氧尿苷或 5-碘脱氧尿苷具有特异性。
• Microorganisms detection methods and the separation of agglutinated microorganisms, and a kit for use therein
  申请人：E-Y LABORATORIES, INC.

  公开号：EP0122023A1

  公开（公告）日：1984-10-17

  A test for the differential detection of suspected N. gonorrhoeae (N.g.) and N. meningitidis (N.m.) in provided by contacting a suspected sample with a lectin, preferably wheat germ agglutinin and either soy bean agglutinin or STA potato lectin. An agglutinin reaction is a positive indication of the presence of such microorganisms. Separate portions of the specimen may be contaced with fast substrates specific for (a) N.g., (b) N.m., and (c) B. catarrhalis. Suitable fast substrates are proline naphthylamide, gamma glutamyl naphthylamide, and glycyl prolyl naphthylamide, respectively, each substituted with an electron donating group at the 4-position, 6-position, or both. Another portion of the specimen may be reacted with a substrate for beta-galactosidase enzyme, a positive reaction being an indication that the specimen contains N.lactimica. Autoagglutination, which could otherwise give a false positive in the lectin test, may be prevented by pretreatment of the specimen with DNA'ase and/or an anhydride such as succinic anhydride.

  一种用于鉴别检测疑似淋球菌（N.g.）和脑膜炎双球菌（N.m.）的检测方法是将疑似样本与凝集素（最好是小麦胚芽凝集素和大豆凝集素或 STA 马铃薯凝集素）接触。凝集素反应是此类微生物存在的阳性指标。标本的不同部分可分别与(a) N.g.、(b) N.m.和(c) B. catarrhalis 的特异性快速底物反应。合适的快速底物分别是脯氨酸萘甲酰胺、γ-谷氨酰萘甲酰胺和甘氨酰脯氨酰萘甲酰胺，每种底物都在 4 位、6 位或两者上被电子捐赠基团取代。标本的另一部分可与β-半乳糖苷酶的底物反应，阳性反应表明标本中含有乳酸奈米卡氏菌。用 DNA'ase 和/或酸酐（如琥珀酸酐）对标本进行预处理，可防止自身凝集，否则会在凝集素检测中出现假阳性。